Referred to the Committee on Veterans' Affairs, and in addition to the Committee on Armed Services, for a period to be subsequently determined by the Speaker, in each case for con…
This bill ties cost-sharing for certain prescription drugs for TRICARE beneficiaries and veterans to the amounts Medicare Part D beneficiaries pay for the same 'selected drugs' under the Medicare Drug Price Negotiation Program.
It also requires manufacturers signing VA master procurement agreements to set maximum prices at or below the Drug Price Negotiation Program's maximum fair price for those selected drugs.
The changes apply to existing and future master agreements while the Drug Price Negotiation Program is in effect, and require modification if that Program ends.
Technically focused, beneficiary-friendly changes improve chances, but pharma opposition and Senate procedural barriers lower standalone prospects.
Relative to its intended legislative type, this bill clearly and specifically amends federal statutes to cap beneficiary cost‑sharing and Federal procurement prices for 'selected drugs' by referencing the Drug Price Negotiation Program's negotiated prices. It integrates cleanly with existing statutory definitions and includes applicability and termination mechanics for master agreements.
Liberal emphasizes beneficiary savings and equity benefits
Liberal emphasizes beneficiary savings and equity benefits
Likely broadly supportive.
The bill reduces out-of-pocket costs for servicemembers and veterans by anchoring their copays to Medicare-negotiated prices.
It also extends negotiation-based price restraints to federal procurement, which aligns with priorities to lower drug costs and improve equity in access.
Cautiously favorable but pragmatic.
The bill targets lower beneficiary costs and leverages an existing negotiation framework, which is sensible.
However, it raises implementation and contracting questions for DoD, VA, and TRICARE and uncertain budgetary effects, so careful oversight and technical fixes would be sought.
Likely opposed or wary.
The bill imposes price limits tied to Medicare negotiation, expanding federal price controls and interfering with private contracts.
Concerns include federal overreach, harm to pharmaceutical innovation incentives, and potential supply or access disruptions for veterans and servicemembers.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically focused, beneficiary-friendly changes improve chances, but pharma opposition and Senate procedural barriers lower standalone prospects.
The bill has not accumulated any surfaced votes yet.
Liberal emphasizes beneficiary savings and equity benefits
Technically focused, beneficiary-friendly changes improve chances, but pharma opposition and Senate procedural barriers lower standalone pr…
Relative to its intended legislative type, this bill clearly and specifically amends federal statutes to cap beneficiary cost‑sharing and Federal procurement prices for 'selected drugs' by referencing the Drug Price Neg…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.